A controlled pilot study on the efficacy of a low dose antibiotic for the treatment of chronic constipation in patients receiving a high fiber diet / A controlled pilot study on the efficacy of a low dose antibiotic for the treatment of chronic constipation in patients receiving a high fiber diet.

BACKGROUND AND AIMS: In a previous uncontrolled experiment, oral vancomycin improved the symptoms (S) of chronic constipation (CC). The aim of this 21 day controlled pilot study was to determine if a low lincomycin dose improved the S of CC patients unresponsive to a high fiber diet. METHODS: On days 0-to-10, patients were randomized to 500 mg oral lincomycin + high fiber (L + F) or to placebo + high fiber (P + F). Participants and patients were blinded. From days 10-to-21, patients were continued solely on the high fiber diet. The primary efficacy endpoint was the difference in S between L + F and P + F from days 0-to-21 using a visual analog scale (VAS) calibrated from 0 = severe S to 10 = asymptomatic. RESULTS: The means of all S were significantly improved by L + F but not by P + F. A significant higher proportion of L + F patients increased the VAS > or = 3 points. CONCLUSIONS: The initial course of L facilitated the effect of F probably by its effect on the colon flora. This sequence of flora-altering biologics + F may serve as model to replace chronic use of drugs.

Therapeutic Effect of Topical Application of Linoleic Acid and Lincomycin in Combination with Betamethasone Valerate in Melasma Patients

Melasma is an acquired symmetric hypermelanosis characterized by irregular lightto gray-brown macules and patches on sun-exposed areas. Many therapeutic agents are available but are unsatisfactory. Recently, it has been demonstrated that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients. Fortyseven Korean female adults with clinically diagnosed melasma were enrolled in a 6-week, double-blind, randomized clinical trial. Patients were treated with one application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or 2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Determination of efficacy was based on the Melasma Area and Severity Index (MASI) score and objective assessment (no effect, mild, moderate, or excellent) at intervals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison with the pre-treatment MASI score, the average MASI score of group C decreased to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There was no statistically significant difference between group A and group B. Seven patients (43.7%) in group C revealed more than moderate improvement in objective assessment, compared with none in group A and two patients (12.5%) in group B. There were no significant side effects. Topical application of linoleic acid is considered to be effective in the treatment of melasma patients.

A pilot study of parenteral lincomycin therapy in soft tissue infections.

From our study it is clear that lincomycin, given 300 mg intra muscularly daily in a single dose, is effective in a wide range of soft tissue infections especially those involving the head and neck region. An overall success rate of 88.8 per cent was observed in the 150 patients selected for the study. It is significant that in none of the subjects was any untoward reaction observed or reported. Hitherto all the previous systematic surveys on lincomycin appear to have been carried out on bone infections where, undoubtedly, lincomycin is highly effective. This pilot study furnishes an encouraging report on the successful treatment of soft tissue infections with parenteral lincomycin.

Ceforanida vs lincomicina en el tratamiento de las amigdalofaringitis agudas por estreptococo beta hemolitico del grupo A (EBHA> / Cephoranide vs lincomycin in the treatment of acute tonsillo-pharyngitis due to beta hemolitic streptococcus group A (EBHA)

Presentamos los resultados de un estudio comparativo entre la nueva cefalosporina ceforanida y la lincomicina, administradas por via muscular, una dosis diaria, en 40 ninos con amigdalo-faringitis por estretococo b hemolitico del grupo A. La efectividad clinica fue del 100% y la bacteriologica del 95% con ambos antibioticos. Las recaidas bacteriologicas fueron del 10% con ceforanida y del 5% con lincomicina. Se comenta la antibioterapia de las amigdalo-faringitis por EBHA agudas y cronicas

Níveis sericos e tissulares (amigdalianos) de lincomicina em seguida a administraçäo de dose única de 1.2g IM/24h

Foram estudados, dois grupos de pacientes adultos que receberam doses únicas (1.2g) de Licomicina. Um grupo de 7 pacientes foi amigdalectomizado, de 10 a 12 horas após a aplicaçäo e outro grupo de 13 pacientes, após 22 a 24 horas. Em ambos grupos os níveis tissulares da droga foram dosados. Os níveis séricos foram medidos em ambos os grupos, com: 0, 2, 3, 8, 12 e 24 horas. Os resultados säo apresentados. Embora no grupo de 12 horas os níveis tissulares amigdalianos tenham sido maiores, os níveis obtidos no grupo de 24 horas revelaram-se eficientes do ponto de vista terapêutico para Streptococcus (pyogenes e pneumoniae)

Eficacia de la lincomicina en el tratamiento de la amigdalitis aguda / Efficacy of lincomicyn in the treatment of acute amigdalitis

Se estudiaron 48 pacientes con cuadro clínico de faringo-amigdalitis pultácea. Sólo en 32 pacientes se aisló Streptococcus beta-hemolítico Grupo A. Sin embargo a todos los pacientes estudiados y posterior a la toma de cultivo y exámenes de sangre, se les trató con lincomicina 1 gr. por vía intramuscular y luego 500 mgrs. cada 8 horas por vía oral hasta completar 10 días. Se usó lincomicina ya que ha demostrado ser un agente efectivo contra el Streptococcus beta hemolítico Grupo A, la concentración en el tejido amigdaliano llega a niveles que van de 9,52 mcg/gr. hasta 23,26 mcg/gr. y tiene gran afinidad para penetrar al núcleo de la amígdala y erradicar tanto a las bacterias anaeróbicas como a los Staphylococcus productores de beta-lactamasa, motivo de su mayor efectividad. La sensibilidad de las cepas se determinó por técnicas de Concentración Inhibitoria Mínima (CIM); y los antibióticos probados fueron: penicilina, meticilina, ampicilina, cefalotina, eritromicina, lincomicina y vancomicina. El resultado de la terapia fue excelente, no se manifestaron reacciones adversas, sólo en un paciente se presentó diarrea al décimo día de tratamiento, no siendo necesaria la suspensión de la terapia

Sobreusos de tecnologías medicas: racionalidad en la formulacion de lincosaminas / Overuse of medical technology. Rationality of lincosamines formulation

Se presentan los resultados de un estudio descriptivo sobre la racionalidad del uso de las lincosaminas en el total de los pacientes ambulatorios que fueron formulados en un día corriente laborable en el Instituto de Seguros Sociales (ISS) de la seccional Bogotá. Este estudio se hizo con base en la información consignada en las formulas médicas individuales y en los datos de la historia clínica que fundamentaron el diagnóstico o describieron el problema que originó la consulta del paciente. Esta informacion se cotejó con un listado de normas guia para la auditoría del uso de lincosaminas elaboradas por la Administración de Veteranos de los Estados Unidos. Los resultados señalan un empleo completamente injustificado de dichos antibióticos además de una inapropiada formulación de la dosis y duración del tratamiento. Se discuten las implicaciones que sobre la evaluación del uso de tecnologías médicas y sobre la evaluación de la calidad tienen los programas computadorizados como los que en el área de farmacia lleva el ISS en la seccional de Bogotá-Cundinamarca y que sirvieron de fuente de datos de la presente investigación